

1  
2 Age at first birth in women is genetically associated with increased risk of  
3 schizophrenia  
4

5 Guiyan Ni,<sup>1</sup> Jacob Gratten,<sup>2,3</sup> Schizophrenia Working Group of the Psychiatric Genomics  
6 Consortium<sup>4</sup>, Naomi R. Wray,<sup>2,3</sup> and S. Hong Lee<sup>1,3,5\*</sup>

7  
8 <sup>1</sup>School of Environmental and Rural Science, University of New England, Armidale, NSW,  
9 2351, Australia

10 <sup>2</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072,  
11 Australia.

12 <sup>3</sup>Queensland Brain Institute, University of Queensland, Brisbane, Queensland, 4072, Australia.

13 <sup>4</sup>A list of authors in the Supplementary file

14 <sup>5</sup>Centre for Population Health Research, School of Health Sciences and Sansom Institute of  
15 Health Research, University of South Australia, Adelaide, Australia

16

17 Guiyan Ni: Guiyan.ni@une.edu.au

18 Jacob Gratten: j.gratten@imb.uq.edu.au

19 Naomi R. Wray: naomi.wray@uq.edu.au

20 \*S. Hong Lee: hong.lee@une.edu.au

21

22 KEYWORDS:

23 Schizophrenia, Age at first birth, Risk profile score, GBLUP, GREML

24 ABSTRACT


25 Previous studies have shown an increased risk for a range of mental health issues in children  
26 born to both younger and older parents compared to children of average-aged parents. However,  
27 until recently, it was not clear if these increased risks are due to psychosocial factors associated  
28 with age or if parents at higher genetic risk for psychiatric disorders tend to have children at an  
29 earlier or later age. We previously used a novel design to reveal a latent mechanism of genetic  
30 association between schizophrenia and age of mothers at the birth of their first child (AFB).  
31 Here, we use independent data from the UK Biobank (N=38,892) to replicate the finding of an  
32 association between predicted genetic risk of schizophrenia and AFB in women, and to estimate  
33 the genetic correlation between schizophrenia and AFB in women stratified into younger and  
34 older groups. We find evidence for an association between predicted genetic risk of  
35 schizophrenia and AFB in women (P-value=1.12E-05), and we show genetic heterogeneity  
36 between younger and older AFB groups (P-value=3.45E-03). The genetic correlation between  
37 schizophrenia and AFB in the younger AFB group is -0.16 (SE=0.04) while that between  
38 schizophrenia and AFB in the older AFB group is 0.14 (SE=0.08). Our results suggest that early,  
39 and perhaps also late, age at first birth in women is associated with increased genetic risk for  
40 schizophrenia. These findings contribute new insights into factors contributing to the complex  
41 bio-social risk architecture underpinning the association between parental age and offspring  
42 mental health.

43

44

45 INTRODUCTION

46 An increased risk for a range of mental health issues in children born to both younger and older  
47 parents compared to children of average-aged parents has been reported in many studies<sup>1-8</sup>, with  
48 particular focus on risk of schizophrenia (SCZ) in children associated with parental age<sup>9-12</sup>. A  
49 recent comprehensive analysis using family data extracted from the Danish Psychiatric Central  
50 Register reported a relationship between mother's age and risk of schizophrenia in her  
51 offspring<sup>13</sup>. They showed that there was higher risk in children of younger and older mothers  
52 compared to those of intermediate age (25-29 years – i.e. a U-shaped relationship between  
53 maternal age and risk of SCZ in offspring), but it was unclear if this was due to psychosocial  
54 factors associated with maternal age or if mothers at higher genetic risk for SCZ tend to have  
55 children at an earlier or later age. Moreover, the very high correlation in spousal ages makes  
56 paternal and maternal contributions to this relationship difficult to disentangle. A number of  
57 possible latent mechanisms behind these epidemiological observations have been proposed<sup>14</sup>,  
58 including shared genetic risk factors between parents and offspring<sup>15,16</sup> (Figure 1). A better  
59 understanding of factors contributing to the relationship between parental age and risk of  
60 psychiatric disorders is important for informing any future public health initiatives targeting this  
61 relationship.



62

63 **Figure 1. A flowchart of suggested mechanisms contributing to the relationship between**  
64 **the parental age and the schizophrenia risk in offspring.**

65

66 We have previously reported evidence for a genetic relationship between maternal age at first  
67 birth (AFB) and risk of SCZ<sup>17</sup>, as illustrated in red in Figure 1. We employed a novel design that  
68 directly tests the genetic risk of schizophrenia in mothers depending on AFB. In all previous  
69 study designs the psychiatric disorder was measured in the child, and hence the relationship with  
70 AFB in the mother was confounded with characteristics of the father. Here, and in our previous  
71 study we examine the relationship between SCZ and AFB by using a genetic predictor of  
72 schizophrenia in the mother. The analyses use community samples of women enrolled in  
73 research studies that were not enriched for psychiatric disorders (< 1% for diagnosis with  
74 schizophrenia). The genetic predictor for schizophrenia can be calculated for all women in the

75 studies as a function (such as weighted sum) of the schizophrenia risk alleles they carry, with the  
76 risk alleles identified in published genome-wide association studies (GWAS) as having increased  
77 frequencies in SCZ cases compared to controls. A woman's genetic risk for schizophrenia is  
78 solely a function of her DNA, which she received independently of the characteristics of her  
79 partner. Hence, a benefit of this novel design is that the inferred association is not confounded by  
80 artefactual or non-genetic association(s) such as increased SCZ risk in offspring due to maternal  
81 environmental effects or by confounding with father's age. We showed that the U-shaped  
82 relationship (between maternal age at birth and SCZ risk in offspring) observed in  
83 epidemiological studies was also observed when considering predicted genetic risk for SCZ as a  
84 function of AFB in healthy women <sup>13,17</sup>.

85  
86 In this study, we replicate and extend our earlier findings <sup>17</sup> using the UK Biobank data in which  
87 community samples of women have been measured for AFB. First, we confirm that SCZ  
88 polygenic risk score (PRS) for women in the UK Biobank with a record of AFB (N = 38,892)  
89 significantly predicts the U-shaped relationship found in McGrath et al.<sup>13</sup>, thereby replicating the  
90 results in Mehta et al.<sup>17</sup>. Second, we test if there is a genetic heterogeneity for AFB between  
91 younger and older AFB groups. Third, we estimate the genetic correlation between SCZ and  
92 AFB in younger and older AFB groups.

93

94

95 RESULTS

96 Overview

97 In total, 41,630 SCZ GWAS samples including 18,957 cases and 22,673 controls from 33  
98 cohorts were used in the current study (Table S1), which were the same data used in Mehta et  
99 al.<sup>17</sup>. For the UK Biobank sample, 38,892 women were used in current study. The distribution of  
100 AFB, age at interview, and year of birth for the UK Biobank data after QC is shown in Figure  
101 S1. In total, 518,992 SNPs passed the quality control criteria and were in common across the  
102 SCZ and UK Biobank samples. The distribution of MAF is shown in Figure S2. Figure S3 shows  
103 that there were no closely related individuals in the UK Biobank and SCZ case-control data sets,  
104 making sure that the two data sets were independent.


105 We estimated SCZ polygenic risk cores (PRS) for each individual in the UK Biobank sample,  
106 using the SCZ GWAS as a reference data set (see Methods). We used both the standard genetic  
107 profile score approach<sup>18</sup> (PRS-score) and the theoretically superior method of Genomic Best  
108 Linear Unbiased Prediction (PRS-GBLUP). We assessed the U-shaped relationship between  
109 AFB and SCZ PRS for the UK Biobank sample. We emphasize that in this novel design, it was  
110 not necessary to measure SCZ risk in offspring, and in our strategy potential confounding due to  
111 a correlation between paternal and maternal age was mostly removed.

112 Subsequently, we estimated SNP-heritability and genetic correlation between AFB and SCZ.  
113 Because of the non-linear relationship (U-shape), we divided the UK Biobank sample into two  
114 groups with younger and older AFB. We assessed if the younger and older AFB groups were  
115 genetically heterogeneous, and if there is any significant genetic correlation between SCZ and  
116 each of the younger and older AFB groups.

117

118 **Relationship between SCZ PRS and AFB**

119 Consistent with McGrath et al.<sup>13</sup> and replicating the findings in Mehta et al.<sup>17</sup>, a U-shaped  
120 relationship was observed between AFB and SCZ PRS-GBLUP (Figure 2). The mean SCZ PRS-  
121 GBLUP in women with early AFB (<20 years) was significantly higher than that in women with  
122 intermediate AFB (P= 2.2E-02 for AFB between 20 to < 25 years, P=1.2E-05 for AFB between  
123 25 to < 30 years, P=2.0E-02 for AFB between 30 to < 35 years, in Table S2), but not in women  
124 with high AFB (P=4.9E-01 for AFB  $\geq$ 35 years). The mean SCZ PRS-GBLUP in women with  
125 AFB between 25 to < 30 years was significantly lower than that in women with AFB between 20  
126 to < 25 years (P=2.0E-03). Our results confirmed the findings in Mehta et al.<sup>17</sup> and with stronger  
127 significance, both when PRS was calculated using GBLUP (PRS-GBLUP) and when using  
128 conventional profile scoring based on GWAS summary statistics from the SCZ GWAS data  
129 (PRS-score) (Figure S4 and Table S2). We also confirmed that the U-shaped relationship was  
130 replicated with estimated SNP effects from the full SCZ GWAS study (PRS-scorePGC) (See  
131 Figure S4 and Table S3), although these results could be biased due to possible sample overlap  
132 or the presence of relatives between the UK Biobank and the full SCZ data.




133  
134 **Figure 2. Mean and standard error of schizophrenia polygenic risk scores estimated from**  
135 **Genomic Best Linear Unbiased Prediction (GBLUP) in the UK Biobank sample grouped**  
136 **by age at first birth.**

137

138 **Linear predictor**

139 Following Mehta et al.<sup>17</sup>, we tested if SCZ PRS could predict the response variable that  
140 described the relationship between SCZ risk in offspring and maternal age derived in McGrath et  
141 al.<sup>13</sup>. Figure 3 shows that the response variable was significantly predicted by SCZ PRS for the  
142 group with the full range of AFB (P-value = 1.12E-05 for PRS-GBLUP, and P-value = 3.53E-07  
143 for PRS-score and P-value = 3.08E-06 for PRS-scorePGC) and the subgroup with AFB younger  
144 than 26 (P-value = 4.71E-06, 6.06E-08 and 2.45E-06 for PRS-GBLUP, PRS-score and PRS-  
145 scorePGC, respectively), but not for the subgroup with AFB older than 26. The prediction with  
146 PRS-score was stronger than that with PRS-scorePGC, and both stronger than that with PRS-  
147 GBLUP.



148

149 **Figure 3.  $-\log(P)$  values for the null hypothesis of  $R^2 = 0$  based on the linear prediction.** Full  
150 range of AFB: All available samples with a record of age at first birth were used. AFB < 26  
151 ( $\geq 26$ ): Analyses were only focus on samples with AFB < 26 ( $\geq 26$ ). PRS-GBLUP: Schizophrenia  
152 (SCZ) polygenic risk scores estimated from genomic best linear unbiased prediction were used  
153 as an explanatory variable in the model. PRS-score: SCZ polygenic risk scores estimated from  
154 genome-wide association study based on available individual genotype data were used as an  
155 explanatory variable in the model. PRS-scorePGC: SCZ polygenic risk scores estimated from  
156 summary statistics results of full PGC SCZ GWAS study were used as an explanatory variable in  
157 the model. Response variables were generated with a polynomial function derived by Mehta et  
158 al. 17, which describes the relationship between SCZ risk in offspring and maternal age ( $Z =$   
159  $2.7214 - 0.1105X + 0.0018X^2$ , where  $X$  is age at first birth), and used in the model in which the  
160 AFB phenotypes were adjusted for age at interview, year of birth, assessment center at which  
161 participant consented, genotype batch, and the first 20 principal components.

162


163 Education level, income level, smoking and alcohol drinker status were additionally used to  
164 adjust the response variable in the linear prediction to test if those factors diminish the signals.  
165 Even with this conservative model, our results for the group with full range of AFB and the  
166 subgroup with AFB younger than 26 remained significant (Figure S5 and Table S4), albeit with  
167 reduced effect size and significance. The reduced significance might be partly explained by the  
168 reduced sample size (i.e. for full range of AFB, N= 38,892 in the base model and 31,848 in  
169 model adjusted for education and income; see Table S4). In sensitivity analyses we also  
170 restricted the sample to those recruited at age  $\geq 45$  years (N=35,451), which included the vast  
171 majority of women with a record of AFB, so that results were not biased by the exclusion of  
172 women with no reported AFB measure. We found that there was no substantive difference in our  
173 results despite the reduced sample size (Table S4 vs. Table S5).  
174 The UK Biobank sample was divided into two subgroups born before or after 1945, a boundary  
175 of postponement of AFB based on the theory of the second democratic transition<sup>19</sup>. For  
176 individuals born after 1945, PRS-GBLUP significantly predicted the response variable for the  
177 group with the full range of AFB and the subgroup with AFB younger than 26, even after  
178 adjusting for socioeconomic status, and smoking and alcohol drinker status, but not for the  
179 subgroup with older AFB. For individuals born before 1945, PRS-GBLUP did not significantly  
180 predict the response variable for the group with the full range of AFB (P-value = 6.52E-02) nor  
181 the subgroup with AFB younger or older than 26 (P-value = 4.99E-02 or 4.38E-01) (Table S6).  
182 Our results agreed with the results of Mehta et al.<sup>17</sup> in that SCZ PRS of women significantly  
183 predicted the response variable for the group with the full range of AFB and the subgroup with  
184 AFB younger than 26. The signals became stronger for the individuals born after year 1945.  
185

186 **Genetic correlation between AFB and SCZ**

187 Given that the AFB for women in the UK Biobank data was significantly predicted by PRS-  
188 GBLUP (P-value=1.12E-05 and  $R^2$ =4.96E-04 in Table S4), it was of interest to estimate the  
189 genetic correlation between AFB and SCZ, which is the scaled proportion of variance that AFB  
190 and SCZ share due to genetic factors.

191 The SNP-heritability was 0.03 (SE=0.01), 0.10 (SE=0.01), and 0.20 (SE=0.004), for older AFB,  
192 younger AFB, and SCZ, respectively. The SNP-heritability for the older AFB group was not  
193 significantly different from 0 (Figure 4 right panel).

194



195

196 **Figure 4. Genetic correlation (left) and heritability (right) of age at first birth (AFB) ≥ 26,**  
197 **AFB < 26, and schizophrenia (SCZ).** Cor(AFB<26, AFB ≥ 26): Estimated genetic correlation  
198 between the groups with AFB < 26 and with AFB ≥ 26. Cor(SCZ, AFB≥26): Estimated genetic  
199 correlation between SCZ and AFB in the older AFB group. Cor(SCZ, AFB<26): Estimated  
200 genetic correlation between SCZ and AFB in the younger AFB group. The bars are standard  
201 errors. In the model, the AFB phenotypes were adjusted for age at interview, year of birth,  
202 assessment center at which participant consented, genotype batch and the first 20 principal  
203 components. And, the SCZ phenotypes were adjusted for sex, cohorts and the first 20 principal

204 components. The sample size for group AFB  $\geq$  26 was 17,598 and for group AFB<26 was  
205 21,294, and for group SCZ was 41,630.

206

207 The estimated genetic correlation between the younger and older AFB groups was significantly  
208 less than 1 ( $r_g=0.47$ , SE=0.19, P-value=3.45E-03, in Table S7), indicating that younger and older  
209 AFB were genetically heterogeneous in the UK Biobank (Figure 4 left panel). We demonstrate  
210 that a truncated selection had little impact on the estimation of the genetic correlation<sup>20</sup>  
211 (Supplemental Notes 1 and 2 and Figures S6 and S7). Further, the estimated genetic correlation  
212 between SCZ and AFB in the younger AFB group was -0.16 (SE=0.04) and that between SCZ  
213 and AFB in the older AFB group was 0.14 (SE=0.08) (Figure 4 left panel).

214 In sensitivity analyses, education level, income level, smoking and alcohol drinker status were  
215 additionally used to adjust the phenotypes in the GREML analyses to see if those factors change  
216 the estimates. Figure S8 shows that the estimates and their significance were slightly reduced,  
217 which could be partly explained by the decrease of sample size (N=38,892 in the base model  
218 versus 31,848 in the model adjusted for education and income; see Table S7).

219

220 In addition to GREML, linkage disequilibrium score regression (LDSC)<sup>4,21</sup> was applied to  
221 estimate the genetic correlation between SCZ and younger and older AFB (Table S8). As  
222 recommended by the LDSC papers<sup>4,21</sup>, pre-estimated LD scores from the 1000 Genome  
223 reference sample without constraining the intercept of regression were applied to the QCed  
224 GWAS data and full GWAS summary results. However, we could access individual genotype  
225 data and it was clearly known that there was no overlapping sample and no high relatedness in  
226 the QCed GWAS data for which we would be able to use LD scores estimated based on the

227 actual genotype data as well as to constrain the intercept as zero. As reported<sup>4,21</sup>, it was observed  
228 from simulations (Supplemental Note 3) that if there was no overlapping sample, LDSC with  
229 constraining the intercept as zero gave the most accurate estimate with the least standard error  
230 (Figure S9). In the real data analyses, Table S8 showed that LDSC with constraining the  
231 intercept as zero gave similar estimates and standard errors, compared to those from GREML  
232 when using the QCed data. When explicitly estimating the intercept, the standard errors became  
233 large; therefore the precision of estimates might be decreased (Table S8). When using the full  
234 GWAS summary, LDSC gave similar estimates but larger standard errors, compared to GREML  
235 estimates, although a larger SCZ sample size was used for LDSC analyses (77,096 for LDSC vs.  
236 41,630 for GREML).

237

## 238 DISCUSSION

239 Parental age has been consistently associated with an increased risk of SCZ in offspring<sup>9-</sup>  
240 <sup>13,15,16,22,23</sup>, but it is well known that traditional epidemiological study designs, based on data  
241 measured for parental age and SCZ status in their offspring, have limitations with respect to  
242 disentangling genetic effects from non-genetic confounding effects such as common and residual  
243 environmental effects (Figure 1). The elevated risk of SCZ associated with parental age extends  
244 to children of both younger and older parents, compared to children of average aged parents –  
245 i.e. a U-shaped relationship<sup>13</sup>. The most widely accepted mechanism, in the case of delayed  
246 parenthood, is a causal relationship due to the accumulation of *de novo* mutations with age (e.g.  
247 Kong et al.<sup>24</sup>), although this cannot explain increased risk in offspring of younger parents. This  
248 hypothesis is biologically plausible<sup>25-28</sup>, but Gratten et al.<sup>29</sup> have shown using theory and  
249 simulations that paternal age-related *de novo* mutations are unlikely to be the major causal factor

250 responsible for increased risk of SCZ in offspring. Instead, they argued that increased risk of  
251 SCZ in offspring of older fathers could be due to genetic overlap between risk of SCZ and  
252 delayed parenthood. This finding is consistent with epidemiological studies showing that  
253 paternal age at first child, as opposed to paternal age at conception, accounts for the increased  
254 risk of SCZ in the children of older fathers (i.e. arguing against a direct causal role for age-  
255 related *de novo* mutations)<sup>15,16</sup>. Notably, this mechanism of genetic overlap between parental age  
256 and SCZ applies equally well to offspring SCZ risk associated with early parenthood.

257

258 Recently, Mehta et al.<sup>17</sup> used a novel design to investigate the genetic relationship between SCZ  
259 and AFB in women that is free of many of the potential confounders present in epidemiological  
260 study designs (e.g. poor maternity skill, psychosocial factors and shared environmental factors).  
261 Specifically, they used SNP effects obtained using SCZ case-control data to estimate genetic risk  
262 of SCZ in a general community sample of women measured for AFB, finding significant  
263 evidence for pleiotropy between SCZ and AFB. In this analysis, we replicated their results in a  
264 much larger and independent community sample, the UK Biobank study. We confirmed the U-  
265 shaped relationship between AFB and SCZ PRS reported by Mehta et al.<sup>17</sup> (Figures 2 and 3), and  
266 provided evidence of genetic overlap between SCZ and AFB in women. The large number of  
267 samples in the UK Biobank made it possible to also estimate genetic variance and covariance  
268 between SCZ and AFB using a linear mixed model, showing that the traits of younger and older  
269 AFB are genetically heterogeneous (Figure 4 or Table S7). The genetic correlation between SCZ  
270 and AFB in women with AFB<26 was -0.16 (SE = 0.04), which was significantly different from  
271 zero (Figure 4).

272

273 In linear prediction, results from PRS-score were similar to or more significant than those from  
274 PRS-scorePGC (Table S4). This is noteworthy because PRS-scorePGC was based on the GWAS  
275 summary statistics from the full PGC SCZ GWAS (33,640 cases, 43,456 controls), which is a  
276 larger sample than that used to generate PRS-score (individual-level genotype data on 18,957  
277 cases, 22,673 controls). However, publicly available GWAS summary statistics such as those  
278 used for PRS-scorePGC provide incomplete information about sample overlap or pairwise  
279 relationships between data sets, either of which could introduce biases or influence statistical  
280 significance due to non-independence of samples. There is an approach or strategy for  
281 relatedness QC without accessing individual genotypes<sup>30</sup>, however, it is not immediately  
282 applicable to the full PGC data. We hypothesize that the superior performance of PRS-score in  
283 our analysis, despite smaller sample size than PRS-scorePGC (which is explained by restrictions  
284 on data access for individual-level genotype data), reflects the very stringent QC we applied to  
285 the data, including on relatedness.

286  
287 Estimated genetic correlations and their standard errors based on GREML and LDSC were very  
288 similar (Table S8), but only when the intercept of the LDSC was constrained, which requires the  
289 strong assumption of no overlapping samples, and only when LD scores were calculated from  
290 the actual sample, which is usually not possible when using GWAS summary statistics. We also  
291 observed this phenomenon in our results based on simulated data (Supplemental Note 3 and  
292 Figure S9). These observations are in line with the statement in Bulik-Sullivan et al.<sup>21</sup>, that  
293 standard errors are sacrificed to achieve unbiased genetic correlation and the availability of  
294 individual-level genotype data was the most preferable scenario. Nevertheless, the estimated

295 genetic correlations between SCZ, younger AFB and older AFB were consistent using two  
296 different approaches, i.e. GREML and LDSC (Table S8).

297

298 In summary, this study replicated previously reported evidence for significant genetic overlap  
299 between risk of SCZ and AFB in women using an independent target sample from the UK  
300 Biobank. We further showed that AFB in women is genetically heterogeneous (comparing  
301 younger to older AFB) and that there is a significant genetic correlation between SCZ and AFB.  
302 Conducting parallel analyses for AFB in men is of great interest but these data are less easily  
303 available and AFB has not been recorded for men in the UK Biobank. Our results suggest that  
304 early, and perhaps also late, age at first birth in women is associated with increased genetic risk  
305 for schizophrenia. These findings contribute new insights into factors contributing to the  
306 complex bio-social risk architecture underpinning the association between parental age and  
307 offspring mental health.

308

## 309 METHODS AND MATERIALS

### 310 **Participants and quality control**

#### 311 *Schizophrenia (SCZ) sample*

312 Genome-wide association data were available from 18,987 SCZ cases and 22,673 controls from  
313 the second phase of the Psychiatric Genomics Consortium (PGC)<sup>31</sup> with quality control (QC)  
314 applied as described in Mehta et al.<sup>17</sup>. Briefly, the SNP quality control and imputation process  
315 were performed by PGC<sup>31</sup>. The raw genotype data were imputed with IMPUTE2/SHAPEIT<sup>32,33</sup>  
316 using the full 1000 Genomes Project dataset<sup>34</sup> as the reference set. Post-imputation quality  
317 control was performed in each cohort before merging the genotype data across all cohorts, as

318 described elsewhere<sup>17,31</sup>. As in Mehta et al.<sup>17</sup>, we used HapMap3 SNPs that were reliable in  
319 estimating (shared) genetic architecture between complex traits<sup>35-37</sup>. Furthermore, SNPs with call  
320 rate < 0.9, individuals with call rate < 0.9 were excluded. This less stringent QC for call rate was  
321 because SNP and individual QC had been already done by the PGC. After this QC, 688,145  
322 SNPs and 41,630 individuals were remained and used to combine with the UK Biobank sample.

323

324 *UK Biobank sample*

325 In the first version of UK Biobank<sup>38</sup> data set, 80,702 female (54,215 with a recode of AFB) out  
326 of 152,249 genotyped individuals were available from a community sample, in which psychiatric  
327 disorders were not enriched, with 72,355,667 imputed SNPs available.

328 Out of all imputed SNPs, 1,242,190 HapMap3 SNPs were identified, which were filtered through  
329 the following QC filtering criteria: SNPs with imputation INFO < 0.6<sup>17</sup>, minor allele frequency  
330 (MAF) < 0.01, call rate < 0.95, and Hardy-Weinberg equilibrium P-value < 10-7<sup>17</sup> were  
331 excluded. In addition, ambiguous strand SNPs were excluded. After this QC, 930,841 SNPs  
332 remained and they were used to merge with the SCZ SNP list to generate a SNP-list common  
333 between the data sets. For individual level QC, only Caucasian females were used who clustered  
334 within 6 standard deviation from the mean of the EUR reference sample<sup>39</sup> for the first and second  
335 genetic relationship principal components. Individuals were further excluded due to call rate <  
336 0.95. In addition, one in a pair of individuals was randomly removed if their genomic  
337 relationship coefficient was more than 0.05<sup>17</sup>. An important reason for removing closely related  
338 individuals was to reduce the possibility that the similarity between those individuals could be  
339 caused by non-genetic effects (e.g. environment effects)<sup>40</sup>. Furthermore, UK Biobank samples  
340 were excluded if their genomic relationship with any individual in the SCZ or AFB datasets used

341 in Mehta et al.<sup>17</sup> was >0.05, in order to ensure the independence of the UK Biobank sample. The  
342 AFB sample in Mehta et al.<sup>17</sup> included 12,247 genotyped women measured for AFB, who were  
343 from four cohorts: Estonia, the Netherlands, Sweden, and the United Kingdom. After QC, we  
344 used 80,522 individuals (18,957 SCZ cases, 22,673 SCZ controls, and 38,892 UK Biobank  
345 individuals) and 518,992 SNPs in the main analyses.

346

### 347 **Statistical analyses**

348 *Estimation of SCZ polygenic risk score (PRS) in UK Biobank sample*

349 We used a GBLUP model to generate SCZ PRS for each individual in the UK Biobank sample  
350 accounting for the genetic relationship between the UK Biobank sample and the SCZ case-  
351 control sample. The GBLUP model can be written as

352 
$$\mathbf{y} = \mathbf{X}\mathbf{b} + \mathbf{Z}\mathbf{u} + \mathbf{e},$$

353 where  $\mathbf{y}$  is a vector of phenotypic data (i.e. **1**s for SCZ cases, **0**s for SCZ controls and missing for  
354 UK Biobank individuals),  $\mathbf{b}$  represents vectors of fixed effects including sex, cohort and 20  
355 ancestry principal components (PCs),  $\mathbf{u}$  is the vector of SCZ PRS, and  $\mathbf{e}$  is the vector of  
356 residuals.  $\mathbf{X}$  and  $\mathbf{Z}$  are design matrices to allocate effects to phenotypic data. It is assumed that  $\mathbf{u}$   
357 is normally distributed as  $N(0, \mathbf{G}\sigma_u^2)$ , where  $\mathbf{G}$  is the genomic relationship matrix constructed as  
358 described in Yang et al.<sup>41</sup> and  $\sigma_u^2$  is the additive genetic variance, and  $\mathbf{e}$  is normally distributed as  
359  $N(0, \mathbf{I}\sigma_e^2)$ , where  $\mathbf{I}$  is an identify matrix and  $\sigma_e^2$  is the residual variance. GBLUP was performed  
360 using GCTA<sup>41</sup> or MTG2<sup>42,43</sup> so that a subset of  $\mathbf{u}$  for the UK Biobank sample could be inferred  
361 based on the phenotypes of the SCZ sample and the genomic relationships between the two data  
362 sets. Mean SCZ PRS in the UK Biobank individuals grouped by their AFB was estimated to  
363 assess the previously reported U-shaped relationship<sup>13,17</sup>. GBLUP provides more accurate PRS

364 (PRS-GBLUP) under a polygenic genetic architecture than the more standard genetic profile  
365 score approach<sup>18</sup>, but for comparison we also calculated PRS by the standard method (PRS-  
366 score). To estimate SCZ risk SNP effects, an association test was conducted with PLINK 1.9<sup>44</sup>  
367 using the same SCZ GWAS data used in the GBLUP analyses, with phenotypes adjusted for sex,  
368 cohort and 20 PCs. PRS-scores for individuals in the UK Biobank sample were generated by  
369 summing the count of SCZ risk alleles weighted by the SNP effects estimated from the  
370 association test. In addition to PRS-score, we used the estimated SNP effects from the full SCZ  
371 GWAS study (33,640 cases and 43,456 controls; publicly available at  
372 <https://www.med.unc.edu/pgc/><sup>31</sup> to calculate a further profile risk score in the UK Biobank  
373 sample (PRS-scorePGC), although we cannot exclude the possibility of sample overlap or  
374 relatedness between the UKB and PGC SCZ samples.

375

376 *Linear prediction*

377 Using 2,894,688 records from the National Danish Registry, McGrath et al.<sup>13</sup> reported a U-  
378 shaped relationship between risk of SCZ in children and maternal age at birth. The resulting  
379 equation from the U-shaped relationship ( $z = 2.7214 - 0.1105X + 0.0018X^2$ ) can be applied to data  
380 of age at first birth of women to generate predictors of risk of SCZ in their children<sup>17</sup>. We did not  
381 consider the second model in Mehta et al.<sup>17</sup> that was adjusted for partner's ages because the  
382 model was shown to be over-corrected<sup>17</sup>. We calculated the response variable (z) in the UK  
383 Biobank sample from the recorded age at first birth (X) and this was used as the y-variable in  
384 analyses regressing on either PRS-GBLUP, PRS-score or PRS-scorePGC and including age at  
385 interview, assessment center at which participant consented, genotype batch, year of birth and  
386 the first 20 PCs as covariates. Socioeconomic status (i.e. education and income level)<sup>45</sup> or

387 smoking and alcohol drinker status were additionally used to adjust the response variable in  
388 sensitivity analyses (Figure S1). Linear models were applied to the group with the full range of  
389 AFB records, the subgroup with AFB younger than 26 years (< 26), and the subgroup with AFB  
390 at or older than 26 ( $\geq 26$ ), respectively, where the value of 26 is the mean of AFB in the UK  
391 Biobank sample. From the model, the coefficient of determination ( $R^2$ ) and P-value against the  
392 null hypothesis (i.e. SCZ PRS of women is not a predictor of AFB) were estimated.

393

394 *Genomic residual maximum likelihood (GREML)*

395 It is of interest to test if AFB in women is a genetically heterogeneous trait, for instance by  
396 estimating the genetic correlation between younger and older AFB groups. If the genetic  
397 correlation is significantly different from 1, it would imply that the causal variants and/or their  
398 effect sizes differ between younger and older AFB. Moreover, it would be interesting to estimate  
399 genetic correlations between SCZ case-control data and younger or older AFB groups. The UK  
400 Biobank data were divided into two groups by younger (< 26) and older AFB ( $\geq 26$ ). Then,  
401 three-variate linear mixed model analysis was conducted to estimate genetic variance and  
402 covariance between SCZ case-control data, and younger and older AFB groups. The model can  
403 be written as

404  $\mathbf{y}_1 = \mathbf{X}_1 \mathbf{b}_1 + \mathbf{Z}_1 \mathbf{g}_1 + \mathbf{e}_1$  for SCZ sample

405  $\mathbf{y}_2 = \mathbf{X}_2 \mathbf{b}_2 + \mathbf{Z}_2 \mathbf{g}_2 + \mathbf{e}_2$  for UK Biobank sample with AFB  $< 26$

406  $\mathbf{y}_3 = \mathbf{X}_3 \mathbf{b}_3 + \mathbf{Z}_3 \mathbf{g}_3 + \mathbf{e}_3$  for UK Biobank sample with AFB  $\geq 26$

407 where  $\mathbf{y}$  are three column vectors of phenotypic observations (one for each data set or group, i.e.  
408 SCZ case-control data set, UK Biobank AFB  $< 26$  and UK Biobank AFB  $\geq 26$ ). For SCZ case-  
409 control data, pre-adjusted phenotypes corrected for sex, cohort and 20 PCs were used. For the

410 UK Biobank sample, the AFB phenotypes were pre-adjusted for sex, age at interview, year of  
411 birth, assessment center, genotype batch and 20 PCs. Again, other possible confounding factors  
412 such as socioeconomic status, and smoking and alcohol drinker status were additionally  
413 controlled in sensitivity analyses to check if the estimates were substantially changed. The  
414 GREML analyses were conducted with GCTA<sup>41</sup> or MTG2<sup>42,43</sup> to estimate pairwise genetic  
415 correlations among the three data sets; SCZ data, and younger AFB and older AFB.  
416

417

418 **Acknowledgements**

419 This research is supported by the Australian National Health and Medical Research Council  
420 (1080157, 1087889, 1103418, 1127440), and the Australian Research Council (DP160102126,  
421 FT160100229). This research has been conducted using the UK Biobank Resource. UK Biobank  
422 (<http://www.ukbiobank.ac.uk>) Research Ethics Committee (REC) approval number is  
423 11/NW/0382. Our reference number approved by UK Biobank is 14575.

424

425 **Author contributions**

426  
427 S.H.L. conceived the idea and directed the study. G.N. and S.H.L. performed the analyses.  
428 N.R.W. and J.G. provided critical feedback and key elements in interpreting the results. S.H.L.,  
429 N.R.W., G.N. and J.G. drafted the manuscript. All authors contributed to editing and approval of  
430 the final manuscript.

431

432 **Financial disclosures**

433 The authors declare that they have no conflicting interests.

434

435

436 **Reference**

437 1. de Kluiver, H., Buizer-Voskamp, J.E., Dolan, C.V. & Boomsma, D.I. Paternal age and  
438 psychiatric disorders: A review. *American Journal of Medical Genetics Part B:*  
439 *Neuropsychiatric Genetics* (2016).

440 2. Frans, E.M., Lichtenstein, P., Hultman, C.M. & Kuja-Halkola, R. Age at fatherhood:  
441 heritability and associations with psychiatric disorders. *Psychological medicine*, 1-8  
442 (2016).

443 3. Mok, P.L.H., Antonson, S., Pedersen, C.B. & Webb, R.T. Younger or older parental age  
444 and risk of suicidality, premature death, psychiatric illness, and criminality in offspring.  
445 *Journal of Affective Disorders* **208**, 130-138 (2016).

446 4. Bulik-Sullivan, B. *et al.* An Atlas of Genetic Correlations across Human Diseases and  
447 Traits. *Natrure genetics* **47**, 1236-1241 (2015).

448 5. Grattan, R.E. *et al.* Paternal and maternal ages have contrasting associations with self-  
449 reported schizophrenia liability. *Schizophrenia Research* **169**, 308-312 (2015).

450 6. Pearson, G.D. Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia  
451 and bipolar disorder. *Annual review of clinical psychology* **11**, 251-281 (2015).

452 7. Chang, Z. *et al.* Maternal age at childbirth and risk for ADHD in offspring: A population-  
453 based cohort study. *International Journal of Epidemiology* **43**, 1815-1824 (2014).

454 8. D'Onofrio, B.M. *et al.* Paternal age at childbearing and offspring psychiatric and  
455 academic morbidity. *JAMA psychiatry* **71**, 432-8 (2014).

456 9. Malaspina, D., Harlap, S., Fennig, S. & Al, E. Advancing paternal age and the risk of  
457 schizophrenia. *Archives of General Psychiatry* **58**, 361-367 (2001).

458 10. Zammit, S. *et al.* Paternal age and risk for schizophrenia. *Br J Psychiatry* **183**, 405-408  
459 (2003).

460 11. International Schizophrenia Consortium. Common polygenic variation contributes to risk  
461 of schizophrenia that overlaps with bipolar disorder. *Natrue* **100**, 130-134 (2009).

462 12. Lopez-Castroman, J. *et al.* Differences in maternal and paternal age between  
463 Schizophrenia and other psychiatric disorders. *Schizophrenia Research* **116**, 184-190  
464 (2010).

465 13. McGrath, J.J. *et al.* A comprehensive assessment of parental age and psychiatric  
466 disorders. *JAMA psychiatry* **71**, 301-9 (2014).

467 14. Jaffe, A.E., Eaton, W.W., Straub, R.E., Marenco, S. & Weinberger, D.R. Paternal age, de  
468 novo mutations and schizophrenia. *Mol Psychiatry* **19**, 274-275 (2014).

469 15. Petersen, L., Mortensen, P.B. & Pedersen, C.B. Paternal age at birth of first child and risk  
470 of schizophrenia. *The American journal of psychiatry* **168**, 82-8 (2011).

471 16. Pedersen, C.B., McGrath, J., Mortensen, P.B. & Petersen, L. The importance of father' s  
472 age to schizophrenia risk. *Molecular psychiatry*, 530-532 (2014).

473 17. Mehta, D. *et al.* Evidence for genetic overlap between schizophrenia and age at first birth  
474 in women. *JAMA Psychiatry* **73**, 497-505 (2016).

475 18. Wray, N.R. *et al.* Research Review: Polygenic methods and their application to  
476 psychiatric traits. *Journal of Child Psychology and Psychiatry and Allied Disciplines* **55**,  
477 1068-1087 (2014).

478 19. Lesthaeghe, R.J. The unfolding story of the second demographic transition. *Population*  
479 *and Development Review* **36**, 211-251 (2010).

480 20. Lee, S.H., Weerasinghe, W.M.S.P. & van der Werf, J.H.J. Genotype-environment  
481 interaction on human cognitive function conditioned on the status of breastfeeding and  
482 maternal smoking around birth. *Scientific Reports* **7**, 6087 (2017).

483 21. Bulik-sullivan, B.K. *et al.* LD Score regression distinguishes confounding from  
484 polygenicity in genome-wide association studies. **47**, 291-295 (2015).

485 22. Frans, E.M. *et al.* Autism Risk Across Generations: A Population Based Study of  
486 Advancing Grandpaternal and Paternal Age. *JAMA psychiatry (Chicago, Ill.)* **70**, 516-521  
487 (2013).

488 23. Hultman, C.M., Sandin, S., Levine, S.Z., Lichtenstein, P. & Reichenberg, A. Advancing  
489 paternal age and risk of autism: new evidence from a population-based study and a meta-  
490 analysis of epidemiological studies. *Mol Psychiatry* **16**, 1203-1212 (2011).

491 24. Kong, A. *et al.* Rate of de novo mutations and the importance of father's age to disease  
492 risk. *Nature* **488**, 471-5 (2012).

493 25. Crow, J.F. The high spontaneous mutation rate: Is it a health risk? *Proceedings of the  
494 National Academy of Sciences* **94**, 8380-8386 (1997).

495 26. Haldane, J.B.S. The mutation rate of the gene for haemophilia, and its segregation ratios  
496 in males and females. *Annals of Eugenics* **13**, 262-271 (1947).

497 27. Vogel, F. & Rathenberg, R. Spontaneous Mutation in Man. in *Advances in Human  
498 Genetics* (eds. Harris, H. & Hirschhorn, K.) 223-318 (Springer US, Boston, MA, 1975).

499 28. Crow, J.F. The origins, patterns and implications of human spontaneous mutation. *Nat  
500 Rev Genet* **1**, 40-47 (2000).

501 29. Gratten, J. *et al.* Risk of psychiatric illness from advanced paternal age is not  
502 predominantly from de novo mutations. *Nature Genetics* **48**, 718-724 (2016).

503 30. Chen, G.-B. *et al.* Across-cohort QC analyses of genome-wide association study  
504 summary statistics from complex traits. *European journal of human genetics*, 1-10  
505 (2016).

506 31. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological  
507 insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421-427 (2014).

508 32. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of  
509 genomes. *G3 (Bethesda, Md.)* **1**, 457-70 (2011).

510 33. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for  
511 thousands of genomes. *Nature methods* **9**, 179-81 (2012).

512 34. McVean, G.A. *et al.* An integrated map of genetic variation from 1,092 human genomes.  
513 *Nature* **491**, 56-65 (2012).

514 35. Ripke, S. *et al.* Genome-wide association analysis identifies 13 new risk loci for  
515 schizophrenia. *Nature genetics* **45**, 1-26 (2013).

516 36. Lee, S.H. *et al.* Estimation of SNP heritability from dense genotype data. *American  
517 Journal of Human Genetics* **93**, 1151-1155 (2013).

518 37. Tropf, F.C. *et al.* Human fertility, molecular genetics, and natural selection in modern  
519 societies. *PLoS ONE* **10**, 1-14 (2015).

520 38. Collins, R. What makes UK Biobank special? *The Lancet* **379**, 1173-1174 (2012).

521 39. The Genomes Project Consortium. A global reference for human genetic variation.  
522 *Nature* **526**, 68-74 (2015).

523 40. Yang, J. *et al.* Common SNPs explain a large proportion of heritability for human height.  
524 *Natruve Genetics* **42**, 565-569 (2010).

525 41. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: A tool for genome-wide  
526 complex trait analysis. *American Journal of Human Genetics* **88**, 76-82 (2011).

527 42. Lee, S.H. & van der Werf, J. MTG2: An efficient algorithm for multivariate linear mixed  
528 model analysis based on genomic information. *Bioinformatics* **32**, 1420-1422 (2016).

529 43. Maier, R. *et al.* Joint analysis of psychiatric disorders increases accuracy of risk  
530 prediction for schizophrenia, bipolar disorder and major depression disorder. *Am J Hum  
531 Genet* **96**, 283-294 (2015).

532 44. Chang, C.C. *et al.* Second-generation PLINK : rising to the challenge of larger and richer  
533 datasets. *GigaScience* **4**(2015).

534 45. Boivin, J. *et al.* Associations between maternal older age, family environment and parent  
535 and child wellbeing in families using assisted reproductive techniques to conceive. *Social  
536 Science and Medicine* **68**, 1948-1955 (2009).

537